Moderna’s imminent FDA vaccine decision, TCGX launches $400M Asia biotech fund, and more biotech news HECTOR RETAMAL/AFP via Getty Images Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hiya, and welcome back to The Readout. Today, we’re getting ready for the FDA’s upcoming decision on Moderna’s mRNA flu shot, and see both a revived fight over 340B rebates and fresh legal scrutiny for Lilly’s insulin pricing. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Meghana Keshavan covers biotech and contributes to The Readout newsletter.
STAT+: Is there a pharma mega-merger in the making?
Full Article
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.